BEIGENE, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160.8 USD | -0.86% |
|
+0.13% | -10.86% |
| 09/05 | Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up | MT |
| 08/05 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday | MT |
Presenter SpeechRichard Yeh (Analysts)Good morning. My name is Richard Yeh. Welcome here for t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
162.2
USD
Average target price
267
USD
Spread / Average Target
+64.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.86% | 16.96B | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B | |
| +289.58% | 7.98B |
- Stock Market
- Equities
- BGNE Stock
- News BeiGene, Ltd.
- Transcript : BeiGene, Ltd. Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-12-2018 11